Antidepressant Powder Escitalopram Oxalate Promote Sleep CAS 219861-08-2

 

Antidepressant Powder Escitalopram Oxalate Promote Sleep CAS 219861-08-2

 

 

Escitalopram oxalate Spec.
Product Name: Escitalopram oxalate
Synonyms: (S)-CITALOPRAM;1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofuran-carbonitrile oxalate;ESCITALOPRAM OXALATE;S-(+)-CITAPROLAM OXALATE;S-(+)-1-3-(dimethyl-amino)propyl-1-(p-fluorophenyl)-5-phthalancarbonitrileoxalate;ESCIFALOPRAMOXALATE(1S)-1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile Ethanedioate;Cipralex
CAS:219861-08-2
MF: C22H23FN2O5
MW: 414.43
Product Categories: Antidepressant;Heterocyclic Compounds;Intermediates & Fine Chemicals;Neurochemicals;Pharmaceuticals;Isotope Labeled Compounds;Escitalopram;Isotope Labelled Compounds;Aromatics;Chiral Reagents;Heterocycles;Pharmaceutical intermdiate;CHLORESIUM;Other APIs;Inhibitors
Melting point: 152-153°C
storage temp.:-20°C Freezer, Under Inert Atmosphere
Chemical Properties:White Solid
Usage An inhibitor of serotonin (5-HT) uptake. Antidepressant
Usage A labelled inhibitor of serotonin (5-HT) uptake. Antidepressant
Usage antineoplastic

 

 

Escitalopram description
Escitalopram is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults and children over 12 years of age with major depressive disorder (MDD) and generalized anxiety disorder (GAD). Escitalopram is the (S)-stereoisomer (Left-enantiomer) of the earlier Lundbeck drug citalopram, hence the name escitalopram. Whether escitalopram exhibits superior therapeutic properties to citalopram or merely represents an example of "evergreening" is controversial.
Puhopharma specializes in controling the quality and reducing the impurities of Escitalopram oxalate.
Our Escitalopram oxalate is with the best quality and the most competitive price in China.

 

 

Application:
Escitalopram was approved by regulatory authorities for the treatment of major depressive disorder on the basis of four placebo controlled, double-blind trials, three of which demonstrated a statistical superiority to placebo. Nonetheless, considerable controversy exists regarding the superiority of escitalopram to its predecessor citalopram. The importance of this issue follows from the greater cost of escitalopram relative to the generic mixture of isomers citalopram prior to the expiration of the escitalopram patent in 2012, which led to charges of evergreening. Accordingly, this issue has been examined in at least 10 different systematic reviews and meta analyses. The most recent of these have concluded (with caveats in some cases) that escitalopram is modestly superior to citalopram in efficacy and/or tolerability.